What this study is
INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes. A segment of a biopsy performed as standard-of-care for indications, or by center protocol, will be used for gene expression study.
What's being tested
- liver biopsy
Intervention · PROCEDURE
5 mm fragment of liver transplant biopsy taken for clinical indication
Study details
- Official title
- Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation, a Multicenter Study
- Sponsor
- University of Alberta
- Conditions
- Liver Dysfunction
- Enrolling
- 300 people
- Starts
- 2017-12-19
- Est. completion
- 2028-12
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Biopsy for clinical indications
You can't join if
- No consent, pregnant women
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (15)
1 openHenry Ford Transplant Institute
Detroit, Michigan, United States
- Dilip Moonka, MD · ContactDMOONKA1@hfhs.org
- Sierra Foley · ContactSFoley3@hfhs.org
- Marwan Abouljoud, MD · Principal investigator
RecruitingUniversity of California San Francisco, Transplant Research Unit
San Francisco, California, United States
CompletedNorthwestern Memorial Hospital
Chicago, Illinois, United States
CompletedUniversity of Maryland School of Medicine
Baltimore, Maryland, United States
CompletedVanderbilt University Medical Center, Vanderbilt Transplant Center
Nashville, Tennessee, United States
WithdrawnBaylor University Medical Center, Annette C. and Harold C. Simmons Transplant Institute
Dallas, Texas, United States
CompletedTransplant Surgery, VCU Medical Center
Richmond, Virginia, United States
CompletedDivision of Transplant Surgery, University of Washington
Seattle, Washington, United States
Completed
7 sites outside the US
Centenary Institute of Cancer Medicine & Cell Biology, Royal Prince Alfred Hospital
Camperdown, Australia
CompletedUniversity of Alberta, Laboratory Medicine and Pathology
Edmonton, Alberta, Canada
CompletedDep. of Nephrology, Transplantation & Internal Med., Samodzielny Publiczny Szpital Kliniczny im. A. Mieleckiego
Katowice, Poland
CompletedIndependent Public Composite Regional Hospital
Szczecin, Poland
CompletedWarsaw Medical University, Jesus the Child Clinical Hospital
Warsaw, Poland
CompletedWarsaw Medical University, Independent Public Clinical Hospital
Warsaw, Poland
CompletedInstitute for Liver Science, King's College London
London, United Kingdom
Completed
Study team
Sponsor
University of Alberta
Study ID ATAGC04
Principal investigator
Philip F Halloran, MD, PhD
University of Alberta
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.